Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?
- 923 Downloads
Clinical evidence regarding the value of MRI for therapy responses assessment in breast cancer is increasing. The objective of this study is to compare the diagnostic capability of diffusion-weighted MR imaging (DW-MRI) and contrast-enhanced MR imaging (CE-MRI) to evaluate and predict pathological response in breast cancer patients receiving neoadjuvant chemotherapy (NAC). We performed a meta-analysis of all available studies of the diagnostic performance of DW-MRI or CE-MRI to evaluate and predict pathological response to NAC in patients with breast cancer. We determined sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR−), diagnostic odds ratio (DOR) and constructed summary receiver operating characteristic curves using hierarchical regression models. Methodological quality was assessed by QUADAS tool. Thirty-four studies met the inclusion criteria and involved 1,932 pathologically confirmed patients in total. Methodological quality was relatively high. DW-MRI sensitivity was 0.93 (95 % CI 0.82–0.97) and specificity was 0.82 (95 % CI 0.70–0.90). Overall LR+ was 5.09 (95 % CI 3.09–8.38), LR− was 0.09 (95 % CI 0.04–0.22), and DOR was 55.59 (95 % CI 21.80–141.80). CE-MRI sensitivity was 0.68 (95 % CI 0.57–0.77) and specificity was 0.91 (95 % CI 0.87–0.94). Overall LR+ was 7.48 (95 % CI 5.29–10.57), LR− was 0.36 (95 % CI 0.27–0.48), and DOR was 20.98 (95 % CI 13.24–33.24). Our study confirms that DW-MRI is a high sensitive and CE-MRI is a high specific modality in predicting pathological response to NAC in breast cancer patients. The combined use of DW-MRI and CE-MRI has the potential to improve the diagnostic performance in monitoring NAC. Further large prospective studies are warranted to assess the actual value of this combination in breast cancer preoperative treatment screening.
KeywordsDiffusion-weighted MR imaging Contrast-enhanced MR imaging Pathological response Neoadjuvant chemotherapy Breast cancer
Financial support: Shanghai Leading Academic Discipline Project, No. S30203 and Shanghai Jiaotong University School of Medicine Leading Academic Discipline Project.
Conflict of interest
- 8.Liu YH, Ye JM, Xu L et al (2011) Effectiveness of dynamic contrast-enhanced magnetic resonance imaging in evaluating clinical responses to neoadjuvant chemotherapy in breast cancer. Chin Med J (Engl) 124(2):194–198Google Scholar
- 23.Dongfeng H, Daqing M, Erhu J (2012) Dynamic breast magnetic resonance imaging: pretreatment prediction of tumor response to neoadjuvant chemotherapy. Clin Breast Cancer 12(2):94–101Google Scholar
- 35.Hsiang DJ, Yamamoto M, Mehta RS, Su MY, Baick CH, Lane KT, Butler JA (2007) Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab. Arch Surg 142(9):855–861 discussion 860–861PubMedCrossRefGoogle Scholar
- 36.Garimella V, Qutob O, Fox JN, Long ED, Chaturvedi A, Turnbull LW, Drew PJ (2007) Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients. Eur J Surg Oncol 33(2):157–161PubMedCrossRefGoogle Scholar
- 43.Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescutti G, Zuiani C (2004) Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvantchemotherapy. Eur Radiol 14(8):1371–1379PubMedCrossRefGoogle Scholar